Cubist Pharmaceuticals, Inc.

Lexington, MA 02421

Market Performance

NASDAQ: CBSTZ
52 Week Low $N/A

SBIR Award Summary

Total Number of Awards 21
Total Value of Awards $3.3MM
First Award Date 04/01/95
Most Recent Award Date 09/01/05

Key Personnel

Last Name Name Awards Contact
Martinis Susan A Martinis 1
Whoriskey Susan K Whoriskey 3
Shue Youe-Kong Shue 2
Kranz Janice E. Kranz 1
Houman Fariba Houman 1
Chapple Joanne P Chapple 1
Green David W Green 2
Brian Paul Brian 4
Tao Jianshi Tao 3
Galcheva-Gargova Zoya I Galcheva-Gargova 1
Yang Min Yang 1
Gallant Paul L Gallant 1

21 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and life-threatening infections caused by Gram-positive pathogens. The goal...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 08/31/05

DESCRIPTION (provided by applicant): The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and life-threatening infections caused by Gram-positive pathogens. The goal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/03 - 04/30/04

DESCRIPTION (provided by applicant): During the last 40 years many lipopeptide antibiotics have been isolated and characterized. These lipopeptides can be grouped into several categories: 10-membered rings; 8-membered rings; 16-membered rings, etc. The most notable lipopeptide from the 10-membered ring group is daptomycin that is currently prog...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/03 - 12/31/03

DESCRIPTION (provided by applicant): The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and life-threatening infections caused by Gram-positive pathogens. The goal ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/03

DESCRIPTION (provided by applicant): Emergence of antibiotic-resistance has created a medical crisis. Life-threatening bacterial pathogens, such as Staphylococcus aureus and Enterococcus faecalis, have developed widespread resistance to current antibiotics. Infectious disease has become the third leading...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-02-05
Budget: 08/01/02 - 06/30/03

DESCRIPTION (provided by applicant): The recent emergence of Gram positive bacteria which are resistant to many current antiinfective therapies presents a challenge to the pharmaceutical industry: New classes of inhibitory molecules are needed which are substantially different than the previous generation of drugs. This need is heightened in th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 09/29/02

DESCRIPTION (provided by applicant): The increasing occurrence of pathogenic bacteria that are resistant to historically successful antibiotics has driven the need to develop new classes of drugs that have a unique mechanism of action. Gram-negative pathogens pose a serious health threat as they can be the causati...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

DESCRIPTION (provided by applicant): Emergence of antibiotic-resistance has created a medical crisis. Life-threatening bacterial pathogens, such as Staphylococcus aureus and Enterococcus faecalis, have developed widespread resistance to current antibiotics. Infectious disease has become the third leading...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/00 - 08/31/01

The need for novel antibiotics has never been greater. Infectious diseases have become the third leading cause of death in the U.S. The rate of mortality from bacterial infections is increasing every year. One reason for this rise is the development of widespread resistance to currently available antibiotics. We plan to combat this rise in it...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/99 - 08/31/00

The need for novel antibiotics has never been greater. Infectious diseases have become the third leading cause of death in the U.S. The rate of mortality from bacterial infections is increasing every year. One reason for this rise is the development of widespread resistance to currently available antibiotics. We plan to combat this rise in it...

Load More